Press Releases

Teva Investor Meeting December 11
December 11, 2012 08:30 (CET)
Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer
December 10, 2012 07:30 (CET)
Active Biotech's election committee appointed
November 15, 2012 08:30 (CET)
Active Biotech AB Interim report January - September 2012
November 9, 2012 08:30 (CET)
PHASE IIa LAQUINIMOD TRIAL RESULTS SHOW POSITIVE DATA FOR POTENTIAL USE IN ACTIVE CROHN'S DISEASE
October 22, 2012 15:00 (CEST)
Active Biotech's partner Ipsen initiates a proof-of-concept study with tasquinimod in additional cancer indications
October 19, 2012 07:15 (CEST)
Ipsen initiates a phase II "Switch maintenance" trial in metastatic castrate-resistant prostate cancer with tasquinimod
October 3, 2012 18:30 (CEST)
Tasquinimod Biomarker Phase II data presented at ESMO 2012
October 1, 2012 08:30 (CEST)
Active Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference
September 6, 2012 08:30 (CEST)
Active Biotech AB Interim report January - June 2012
August 10, 2012 08:30 (CEST)